IDiyas

For the Inventor, By the Inventor

Old Saybrook, CT, United States of America

Mark Allen Sanner

USPTO Granted Patents = 14

Average Co-Inventor Count = 2.7

ph-index = 6

Forward Citations = 210(Granted Patents)


Company Filing History:

goldMedal14 out of 4,455 
 
Pfizer Corporation
 patents

Years Active: 1998-2007

Loading Chart...
14 patents (USPTO):
1. 7220753 - 2,7-substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors (2007-05-22),
2. 7101885 - Piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams (2006-09-05),
3. 7078529 - Imidazole derivatives (2006-07-18),
4. 6756385 - Imidazole derivatives (2004-06-29),
5. 6720427 - Thiazole derivatives (2004-04-13),
6. 6562964 - Heterocyclic compounds as inhibitors of rotamase enzymes (2003-05-13),
7. 6548502 - Dopamine D4 ligands for the treatment of novelty-seeking disorders (2003-04-15),
8. 6372736 - Heterocyclic compounds as inhibitors of rotamase enzymes (2002-04-16),
9. 6284757 - Pyrrolo[1,2-a]pyrazine derivatives as 5HT1A ligands (2001-09-04),
10. 6231833 - 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors (2001-05-15),
11. 5889010 - Benzimidazole derivatives having dopaminergic activity (1999-03-30),
12. 5883094 - Benzimidazolone derivatives with central dopaminergic activity (1999-03-16),
13. 5852031 - 2,7-substituted octahydro-1H-pyrido�1,2-a!pyrazine derivatives (1998-12-22),
14. 5714487 - 2,7-substituted octahydro-pyrrolo�1,2-a!pyrazine derivatives (1998-02-03),

Title: The Innovative Journey of Mark Allen Sanner

Introduction

Mark Allen Sanner is a prolific inventor based in Old Saybrook, Connecticut, known for his significant contributions to pharmaceutical innovations. With a remarkable portfolio of 14 patents, Sanner has led advancements in the treatment of various mental health disorders, showcasing his commitment to enhancing healthcare through science and technology.

Latest Patents

Among his latest patents, Sanner introduced two groundbreaking inventions:

1. **2,7-Substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives** serve as ligands for serotonin receptors. These substituted pyrido[1,2-a]pyrazines play a crucial role in modulating dopamine receptor subtypes and serotonin (5HT) within the body, indicating their potential utility in treating disorders related to the dopamine and serotonin systems.

2. **Piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams** are designed to address various psychological conditions. The invention encompasses compounds that can be utilized in pharmaceutical compositions to effectively treat or prevent disorders such as anxiety, depression, major depressive disorder, migraines, and several personality disorders.

Career Highlights

Sanner's career is marked by his role at Pfizer Corporation, where he has leveraged his expertise to bring innovative solutions to the market. His dedication to research and development has not only contributed to the advancement of pharmaceutical sciences but also reinforced Pfizer’s reputation as a leader in the healthcare sector.

Collaborations

Throughout his career, Mark Allen Sanner has collaborated with esteemed colleagues such as Anton F Fliri and Chris John Helal. These partnerships have fostered a collaborative environment that encourages the exchange of ideas, ultimately leading to breakthroughs in pharmaceutical research and innovation.

Conclusion

Mark Allen Sanner’s commitment to innovation in the pharmaceutical field is evident through his patents and collaborative achievements. His work not only exemplifies the role of inventors in advancing medical science but also highlights the significance of teamwork in fostering innovative solutions for pressing health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…